Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus

Journal of Clinical Virology

Volumn 30, Issue 4, 2004, Pages 283-290

  Gowans, Eric J ^a   Jones, Kathryn L ^a   Bharadwaj, Mandvi ^b   Jackson, David C ^b  

^a BURNET INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Dendritic cell; Hepatitis C virus; Intravenous drug use; Therapeutic

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C VACCINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA INTERFERON A; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADOPTIVE IMMUNOTHERAPY; BLOOD AUTOTRANSFUSION; BLOOD TRANSFUSION REACTION; CELL FUNCTION; CELLULAR IMMUNITY; COLORECTAL CARCINOMA; DENDRITIC CELL; DISEASE ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; MELANOMA; MOLECULAR BIOLOGY; MYELOMA; NONHUMAN; PERSISTENT INFECTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; TREATMENT INDICATION; VACCINATION; VIRUS CHARACTERIZATION;

DENDRITIC CELLS; HEPACIVIRUS; HEPATITIS ANTIGENS; HEPATITIS C; HUMANS; IMMUNOTHERAPY, ACTIVE; TRANSPLANTATION, AUTOLOGOUS;

EID: 2442712761     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2004.03.006     Document Type: Review

References (80)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341:1999;556-562
2. Auffermann-Gretzinger S., Keeffe E.B., Levy S. Impaired dendritic cell function in patients with chronic, but not resolved, hepatitis C virus infection. Blood. 97:2001;3171-3176
3. Bain C., Fatmi A., Zoulim F., Zarski J.-P., Trepo C., Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology. 120:2001;512-524
4. Bartosch B., Dubuisson J., Cosset F.-L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197:2003;633-642
5. Bertoletti A., Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology. 38:2003;4-13
6. Bassett S.E., Thomas D.L., Brasky K.M., Lanford R.E. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. J. Virol. 73:1999;1118-1126
7. Bichr S., Rende-Fournier R., Vona G., Yamamoto A.-M., Depla E., Maertens G., et al. Detection of neutralizing antibodies to hepatitis C virus using a biliary cell infection model. J. Gen. Virol. 83:2002;1673-1678
8. Carbone F.R., Kurts C., Bennett S.R.M., Miller J.F.A.P., Heath W.R. Cross presentation: a general mechanism for CTL immunity and tolerance. Immunol. Today. 19:1998;368-373
9. Cavanaugh V.J., Guidotti L.G., Chisari F.V. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J. Virol. 71:1997;3236-3243
10. Cella M., Sallusto F., Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Top. Immunol. 9:1997;10-16
11. Chen M., Sallberg M., Sonnerborg A., Weiland O., Mattsson L., Jin L., et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology. 116:1999;135-143
12. Cheney I.W., Lai V.C.H., Zhong W., Brodhag T., Dempsey S., Lim C., et al. Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J. Virol. 76:2002;11148-11154
13. Cooper S., Erickson A.L., Adams E.J., Kansopon J., Weiner A., Chien D., et al. Analysis of a successful immune response against hepatitis C virus. Immunity. 10:1999;439-449
14. + T-helper-cell responses in resolved hepatitis C virus infection. J. Virol. 76:2002;12584-12595
15. + T cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J. Virol. 71:1997;6011-6019
16. Dolganic A., Kodys K., Kopasz A., Marshall C., Do T., Romics L., et al. Hepatitis C virus core and nonstructural protein 3 proteins induce pro-and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J. Immunol. 170:2003;5615-5624
17. Donaldson P.T. The interrelationship between hepatitis C and HLA. Eur. J. Clin. Invest. 29:1999;280-283
18. Dore GJ, Law M, MacDonald M, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003;26:171-84.
19. Drummer H.E., Maerz A., Poumbourios P. Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett. 546:2003;360-385
20. Erickson A.L., Kimura Y., Igarashi S., Eichelberger J., Houghton M., Sidney J., et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity. 15:2001;883-895
21. Farci P., Alter H.J., Wong D.C., Miller R.H., Govindarajan S., Engle R., Sahpior M., Purcell R.H. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralisation. Proc. Natl. Acad. Sci. U.S.A. 91:1994;7792-7796
22. Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpolder J.F., et al. The outcome of acute hepatitis C is predicted by the evolution of the viral quasispecies. Science. 288:2000;339-344
23. Gale M.J. Jr., Korth M.F., Tang N.M., Tan S.L., Hopkins D.A., Dever T.E., et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology. 230:1997;217-227
24. + T cell response in acute hepatitis C. Gastroenterology. 117:1999;933-941
25. Giuberti T., Marin M.G., Ferrari C., Marchelli S., Schianchi C., Degli Antoni A.M., et al. Hepatitis C virus viremia following clinical resolution of acute hepatitis C. J. Hepatol. 20:1994;666-671
26. Gordon S.C. New insights into acute hepatitis C. Gastroenterology. 125:2003;253-256
27. Gowans EJ. Towards a vaccine for the hepatitis C virus. In: Crofts, Dore, Locarnini editors. Hepatitis C. IP Communications, 2001. p. 45-55.
28. Grakoui A., Shoukry N.H., Woollard D.J., Han J.-H., Hanson H.L., Ghrayeb J., et al. HCV persistence and immune evasion in the absence of memory T cell help. Science. 302:2003;659-662
29. + T cells with viral clearance in acute hepatitis C. J. Inf. Dis. 181:2000;1528-1536
30. Guidotti L.G., Chisari F.V. Noncytolytic control of viral infections by the innate and adaptive immune response. Ann. Rev. Immunol. 19:2001;65-91
31. Hart D.N.J. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 90:1997;3245-3287
32. Hauri A.M., Armstrong G.L., Hutin Y.J. The global burden of disease attributable to contaminated injections given in health care settings. Int. J. STD AIDS. 15:2004;7-16
33. Heiser A., Coleman D., Dannull J., Yancey D., Maurice M.A., Lallas C.D., et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109:2002;409-417
34. Hiasa Y., Horiike N., Akbar S.M.F., Saito I., Miyamura T. Low stimulatory capacity of lymphoid dendritic cells expressing hepatitis C virus genes. Biochem. Biophys Res. Commun. 249:1998;90-95
35. Houghton M. Strategies and prospects for vaccination against the hepatitis C viruses. Curr. Top Microbiol. Immunol. 242:2000;327-339
36. Hsu M., Zhang J., Flint M., Logvinoff C., Cheng-Mayer C., Rice C.M., et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. U.S.A. 100:2003;7271-7276
37. Jackson M., Smith B., Bevitt D.J., Steward M., Toms G.L., Bassendine M.F., et al. Comparison of cytotoxic T-lymphocyte responses to hepatitis C virus core protein in uninfected and infected individuals. J. Med. Virol. 58:1999;239-246
38. Jonuleit H., Schimtt E., Steinbrink K., Enk A.H. Dendritic cells as a tool to induce anergic and regulatory T-cells. Trends Immunol. 22:2001;394-400
39. Kanto T., Hayashi N., Takehara T., Tatsumi T., Kuzushita N., Ito A., et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J. Immunol. 162:1999;5584-5591
40. Kato N., Ootsuyama Y., Sekiya H., Ohkoshi O., Nakazawa T., Hijikata M., et al. Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection. J. Virol. 68:1994;1117-1120
41. Kittlesen D.J., Chianese-Bullock K.A., Yao Z.Q., Braciale T.J., Hahn Y.S. Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. J. Clin. Invest. 106:2000;1239-1249
42. Keskinen P., Melen K., Julkunen I. Expression of HCV structural proteins impairs IFN-mediated antiviral response. Virology. 299:2002;164-171
43. Kumar U., Monjardino J., Thomas H.C. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology. 106:1994;1072-1075
44. + T cells: implications for vaccine development. Hepatol. 30:1999;1088-1098
45. Lanford R.E., Guerra B., Chavez D., Bigger C., Brasky K.M., Wang X.-H., et al. Cross-genotype immunity to hepatitis C virus. J. Virol. 78:2004;1575-1581
46. Lasarte J.J., Garcia-Granero M., Lopez A., Casares N., Garcia N., Civeira M.-P., et al. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology. 28:1998;815-822
47. Lavanchy D, McMahon B. Worldwide prevalence and prevention of hepatitis C. In: Liang H, editors. Hepatitis C, San Diego CA. Academic Press; 2001. p. 185-201.
48. Lechner F., Wong D.K.H., Dunbar P.R., Chapman R., Chung R.T., Dohrenwend P., et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191:2000;1499-1512
49. Leigh J.P., Bowlus C.L., Leistikow B., Schenker M. Costs of hepatitis C. Arch. Int. Med. 161:2001;2231-2237
50. Longman RS, Talal AH, Jacobson IM, Albert ML, Rice CM. Patients chronically infected with hepatitis C virus have functional dendritic cells. Blood 2003. First edition online October 2, 2003 DOI 10.1182/blood-2003-04-1339.
51. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomized trial. Lancet. 358:2001;958-965
52. Marcellin P., Boyer N., Gervais A., Martinot M., Pouteau M., Castelnau C., et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann. Intern. Med. 127:1997;875-881
53. Matsui M., Moriya O., Abdel-Aziz N., Matsuura Y., Miyamura T., Akatsuka T. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus. Vaccine. 21:2002;211-220
54. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.l., Lee W.M., Rustgi V.K., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Engl. J. Med. 339:1998;1485-1492
55. Moser M. Dendritic cells in immunity and tolerance-do they display opposite functions. Immunity. 19:2003;5-8
56. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4:1998;269-270
57. Nestle F.O., Banchereau J., Hart D. Dendritic cells: on the move from bench to bedside. Nat. Med. 7:2001;761-765
58. Orland J.R., Wright T.L., Cooper S. Acute hepatitis C. Hepatology. 33:2001;321-327
59. Rehermann B., Chisari F.V. Cell mediated immune response to the hepatitis C virus. Curr. Top Microbiol. Immunol. 242:2000;299-325
60. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest. 21:2003;873-886
61. Rock K.L. A new foreign policy: MHC Class I molecules monitor the outside world. Immunol. Today. 17:1996;131-137
62. Rollier C., Drexhage J.A.R., Verstrepen B.E., Verschoor E.J., Bontrop R.E., Koopman G., et al. Chronic hepatitis C virus infection established and maintained in chimpanzees independent of dendritic cell impairment. Hepatology. 38:2003;851-858
63. + Tcells by dendritic cells expressing hepatitis C virus core and E1 proteins. J. Virol. 76:2002;5062-5070
64. Sarobe P., Lasarte J.J., Zabaleta A., Arribillaga L., Arina A., Melero I., et al. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J. Virol. 77:2003;10862-10871
65. Shiell A. Economic Analyses for the Review of the National Hepatitis C Action Plan. Commonwealth Dept of Health and Family Services, Canberra; 1998.
66. Schuler G., Steinman R.M. Dendritic cells as adjuvants for immune-mediated resistance to tumors. J. Exp. Med. 186:1997;1183-1187
67. Shiratori Y., Imazeki F., Moriyama M., Yano M., Arakawa Y., Yokosuka O., et al. Histologic improvement of fibrosis in pateints with hepatitis C who have sustained response to interferon therapy. Ann. Intern. Med. 132:2000;517-524
68. Thimme R., Oldach D., Chang K.-M., Steiger C., Ray S.C., Chisari F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194:2001;1395-1406
69. Thimme R., Jubkh J., Spangenberg H.C., Weiland S., Pemberton J., Steiger C., et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl. Acad. Sci. U.S.A. 99:2002;15661-15668
70. Thomas H.C., Waters J.A. Future approaches to treatment of chronic hepatitis B and hepatitis C infection. J. Viral. Hep. 4(Suppl. 2):1997;92-97
71. Thomson M., Nascimbeni M., Havert M.B., Major M., Gonzales S., Alter H., et al. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J. Virol. 77:2003;862-870
72. Torresi J., Bharadwaj M., Jackson D.C., Gowans E.J. Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy. Curr. Drug Targets. 5:2004;41-56
73. Tsai S.L., Liaw Y.F., Chen M.H., Huang Cy., Kuo G.C. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatol. 25:1997;449-458
74. Villano S.A., Vlahov D., Nelson K.E., Cohn S., Thomas D.L. Persistence of viremia and the importance of long-term follow up after acute hepatitis C infection. Hepatology. 29:1999;908-914
75. Ward S.M., Lauer G., Isba R., Walker B., Klenerman P. Cellular immune responses against hepatitis C virus the evidence base, 2002. Clin. Exp. Immunol. 128:2002;195-203
76. + T cells in chronic hepatitis C virus infection. J. Immunol. 169:2002;3447-3458
77. Weiner A., Erickson Al., Kansopon J., Crawford K., Muchmore E., Hughes A.L., et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc. Natl. Acad. Sci. U.S.A. 92:1995;2755-2759
78. Young J.W., Inaba K. Dendritic cells as adjuvants for Class I major histocompatibility complex-restricted antitumor activity. J. Exp. Med. 183:1996;7-11
79. Zhu N., Khoshnan A., Schneider R., Matsumoto M., Dennert G., Ware C., et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J. Virol. 72:1998;3691-3697
80. Zibert A., Meisel H., Kraas W., Schulz A., Jung G., Roggendorf M. Early antibody against hypervariable region 1 is associated with acute self limited infections of hepatitis C virus. Hepatology. 25:1997;1245-1249